Figure 2: Changes in TSS-6 (A), VAS symptom (B), VAS QoL (C)
and MS (D) according to the immunotherapy application interval during
COVİD-19 pandemic for adherent (Group 1 + Group 2) and non-adherent
patients (Group 3)
NS = non-significant; A = TSS-6; B = VAS symptom; C =
VAS QoL; D = MS